biotech

230,267 views
413 Discussing
suohaWisdom
·
--
华大智造子公司涌生智能与迈维代谢签约,打造全国首条代谢领域全流程自动化产线!基因测序+代谢质谱领域强强联手,医疗科技自动化大升级!#HealthTech #Biotech $MTL BGISEQ's subsidiary Yongsheng Intelligence partners with Metware to build China's first fully automated metabolic production line! Gene sequencing + metabolic mass spectrometry joining forces, medtech automation upgrade! #HealthTech #Biotech $MTL
华大智造子公司涌生智能与迈维代谢签约,打造全国首条代谢领域全流程自动化产线!基因测序+代谢质谱领域强强联手,医疗科技自动化大升级!#HealthTech #Biotech $MTL

BGISEQ's subsidiary Yongsheng Intelligence partners with Metware to build China's first fully automated metabolic production line! Gene sequencing + metabolic mass spectrometry joining forces, medtech automation upgrade! #HealthTech #Biotech $MTL
·
--
Bullish
Verified
$BIO Realiy Check 💋🎀 🧿 Bio Protocol (BIO) has experienced significant attention driven by the intersection of decentralized science (DeSci) and artificial intelligence narratives. Notably, the token recorded heavy trading volumes fueled by high retail demand in Asian markets like South Korea, positioning it among prominent AI-themed digital assets. On the ecosystem front, development has centered on the OpenLabs AI Research Hub—launched to streamline community-driven biotech funding and on-chain governance—alongside foundational V2 upgrades utilizing the BioXP rewards system. Meanwhile, short-term market price action has settled into a consolidation phase around the $0.019 to $0.020 range amid a broader cautious sentiment. #BioProtocol #Biotech #Reward #Techno {future}(BIOUSDT)
$BIO Realiy Check 💋🎀
🧿
Bio Protocol (BIO) has experienced significant attention driven by the intersection of decentralized science (DeSci) and artificial intelligence narratives. Notably, the token recorded heavy trading volumes fueled by high retail demand in Asian markets like South Korea, positioning it among prominent AI-themed digital assets. On the ecosystem front, development has centered on the OpenLabs AI Research Hub—launched to streamline community-driven biotech funding and on-chain governance—alongside foundational V2 upgrades utilizing the BioXP rewards system. Meanwhile, short-term market price action has settled into a consolidation phase around the $0.019 to $0.020 range amid a broader cautious sentiment.

#BioProtocol #Biotech #Reward #Techno
Amgen stock near $402 before Q3 2026 earnings. The setup: revenue crossed $10B in Q2, guidance raised to $38.2B to $39.4B, and the stock rallied 41% year to date. But management warned operating expenses would rise in the second half. The risk is margin compression. Q2 non-GAAP margin hit 48%. If Q3 expenses climb as warned while revenue meets rather than beats consensus, margins could dip to the low 40s. For a stock at 25x trailing earnings, that compression matters. Watching for: revenue above $9.5B, margin above 44%, and Prolia trajectory. Biosimilar pressure took Prolia and XGEVA down 33% in Q2. Not adding before earnings. Your approach may differ. #AMGN #Amgen #Earnings #Pharma #BioTech
Amgen stock near $402 before Q3 2026 earnings. The setup: revenue crossed $10B in Q2, guidance raised to $38.2B to $39.4B, and the stock rallied 41% year to date. But management warned operating expenses would rise in the second half.

The risk is margin compression. Q2 non-GAAP margin hit 48%. If Q3 expenses climb as warned while revenue meets rather than beats consensus, margins could dip to the low 40s. For a stock at 25x trailing earnings, that compression matters.

Watching for: revenue above $9.5B, margin above 44%, and Prolia trajectory. Biosimilar pressure took Prolia and XGEVA down 33% in Q2. Not adding before earnings. Your approach may differ.

#AMGN #Amgen #Earnings #Pharma #BioTech
从屏幕里的代码到生命基底的原子重构:为什么说全球药企巨头抢滩中国“AI纳米递送”是AI for Science的最硬核里程碑? 过去几年,很多人对AI制药的印象还停留在生成小分子分子的概念PPT上。但真正的医药物理死锁不在设计,而在“递送(Delivery)”。 无论是mRNA疫苗还是核酸基因药物,进入血液后90%都会被肝脏捕获吞噬,根本无法精准穿透血脑屏障或靶向肺部、心脏等关键器官。传统筛选有效LNP(脂质纳米颗粒)全靠化学家盲筛试错,周期长达3-5年。 而如今,生成式AI与分子动力学建模从底层重写了这一规则——通过千万级自主生成脂质库逆向设计,将纳米递送靶向研发从数年压缩到2-3个月,打通8大组织特异性递送,让跨国巨头狂掷11亿美元重金合作。 从算力芯片到纳米载体,科技范式正在将现实世界的物理与生命极限层层凿穿。 $BTC $BNB #AI #Science #BioTech
从屏幕里的代码到生命基底的原子重构:为什么说全球药企巨头抢滩中国“AI纳米递送”是AI for Science的最硬核里程碑?

过去几年,很多人对AI制药的印象还停留在生成小分子分子的概念PPT上。但真正的医药物理死锁不在设计,而在“递送(Delivery)”。
无论是mRNA疫苗还是核酸基因药物,进入血液后90%都会被肝脏捕获吞噬,根本无法精准穿透血脑屏障或靶向肺部、心脏等关键器官。传统筛选有效LNP(脂质纳米颗粒)全靠化学家盲筛试错,周期长达3-5年。

而如今,生成式AI与分子动力学建模从底层重写了这一规则——通过千万级自主生成脂质库逆向设计,将纳米递送靶向研发从数年压缩到2-3个月,打通8大组织特异性递送,让跨国巨头狂掷11亿美元重金合作。
从算力芯片到纳米载体,科技范式正在将现实世界的物理与生命极限层层凿穿。

$BTC $BNB #AI #Science #BioTech
近岸蛋白AI业务刚起步,营收占比不足2%!公司提醒:AI药物研发虽是风口,但技术迭代快、验证周期长、商业化难度大,未来收入不确定性高。投资需谨慎!#AI #生物科技 $RNDR Jinyan Protein's AI business is just starting, contributing less than 2% to revenue! The company warns: while AI drug development is trending, it faces rapid tech changes, long validation cycles, and commercialization challenges. Future revenue remains uncertain. Invest with caution! #AI #Biotech $RNDR
近岸蛋白AI业务刚起步,营收占比不足2%!公司提醒:AI药物研发虽是风口,但技术迭代快、验证周期长、商业化难度大,未来收入不确定性高。投资需谨慎!#AI #生物科技 $RNDR

Jinyan Protein's AI business is just starting, contributing less than 2% to revenue! The company warns: while AI drug development is trending, it faces rapid tech changes, long validation cycles, and commercialization challenges. Future revenue remains uncertain. Invest with caution! #AI #Biotech $RNDR
Genmab暴涨近30%创历史新高:今晚美股生物科技的爆点在这里 美股今晚生物科技(Biotech)真正的风暴眼在丹麦抗体巨头 Genmab($GMAB)。 盘中单日暴力拉升近 30%(+28.3%),股价直接飙至历史新高,高盛和各大投行瞬间大幅上调目标价。 【核心爆点逻辑】 1. 重磅抗癌临床数据炸裂:Genmab 旗下的一款试验性晚期癌症疗法在后期关键临床试验中,将患者的“死亡风险直接降低了 50%”,属于肿瘤领域的重磅突破(Game Changer); 2. 财报双击:同日公布的季度业绩全面超预期(Q3 EPS $0.54 远超预期的 $0.37,营收达 11.6 亿美元); 3. 板块情绪共振:继 ESMO 年会各家 ADC/双抗密集放榜后,Genmab 的重磅数据直接引爆了欧美乃至全球对“抗体创新管线”的重估热潮,Moderna、Alnylam 等生物科技标的盘前全线跟涨。 肿瘤药只要有一款在后期试验把死亡率砍掉一半,就是百亿美元级别的商业化重估。 你觉得这一波 Biotech 暴涨是真突破,还是借消息面的脉冲狂欢?手里的医药标的你选择今晚止盈还是锁仓? $BTC $ETH #Biotech #Genmab #币安广场
Genmab暴涨近30%创历史新高:今晚美股生物科技的爆点在这里

美股今晚生物科技(Biotech)真正的风暴眼在丹麦抗体巨头 Genmab($GMAB)。

盘中单日暴力拉升近 30%(+28.3%),股价直接飙至历史新高,高盛和各大投行瞬间大幅上调目标价。

【核心爆点逻辑】
1. 重磅抗癌临床数据炸裂:Genmab 旗下的一款试验性晚期癌症疗法在后期关键临床试验中,将患者的“死亡风险直接降低了 50%”,属于肿瘤领域的重磅突破(Game Changer);
2. 财报双击:同日公布的季度业绩全面超预期(Q3 EPS $0.54 远超预期的 $0.37,营收达 11.6 亿美元);
3. 板块情绪共振:继 ESMO 年会各家 ADC/双抗密集放榜后,Genmab 的重磅数据直接引爆了欧美乃至全球对“抗体创新管线”的重估热潮,Moderna、Alnylam 等生物科技标的盘前全线跟涨。

肿瘤药只要有一款在后期试验把死亡率砍掉一半,就是百亿美元级别的商业化重估。

你觉得这一波 Biotech 暴涨是真突破,还是借消息面的脉冲狂欢?手里的医药标的你选择今晚止盈还是锁仓?

$BTC $ETH #Biotech #Genmab #币安广场
GMABUS+0.76%
🚀 $MRNA REBOUND AFTER AI‑POWERED CANCER VACCINE DATA! 📈 Entry: 202.63 ⚡ The 17.5% drop to $202.63 was a textbook sell‑the‑news dump, but the price floor at $180.80 held firm, suggesting liquidity was soaked up by smart‑money sharks. 📊 Volume surged as buyers reclaimed the level, turning the dip into a potential springboard. ⚡ Now the Phase 3 INTerpath‑001 readout shows a 42% cut in recurrence risk when paired with Keytruda, and AI giants like OpenAI are locking in biotech partnerships. 🦈 This convergence of clinical data and AI could fuel a fresh upside wave. 💡 💬 Are you loading up on $MRNA or waiting for the next AI catalyst? 👇 ⚠️ Not financial advice. Always manage your risk. 🛡️ 🏷️ #MRNA #AI #Biotech #Breakout 🔥 💎
🚀 $MRNA REBOUND AFTER AI‑POWERED CANCER VACCINE DATA! 📈

Entry: 202.63 ⚡

The 17.5% drop to $202.63 was a textbook sell‑the‑news dump, but the price floor at $180.80 held firm, suggesting liquidity was soaked up by smart‑money sharks. 📊 Volume surged as buyers reclaimed the level, turning the dip into a potential springboard. ⚡

Now the Phase 3 INTerpath‑001 readout shows a 42% cut in recurrence risk when paired with Keytruda, and AI giants like OpenAI are locking in biotech partnerships. 🦈 This convergence of clinical data and AI could fuel a fresh upside wave. 💡

💬 Are you loading up on $MRNA or waiting for the next AI catalyst? 👇

⚠️ Not financial advice. Always manage your risk. 🛡️

🏷️ #MRNA #AI #Biotech #Breakout

🔥 💎
·
--
Bullish
🚨🦟 $GOOGL -BACKED MOSQUITO RELEASE? THE INTERNET IS PANICKING... BUT HERE'S WHAT THEY'RE NOT TELLING YOU 👀👇 32 MILLION mosquitoes could be released in parts of the U.S. 🇺🇸 Sounds terrifying, right? 😳 {future}(GOOGLUSDT) But before you imagine swarms of mutant insects taking over cities... there's a twist. 🧵👇 🔬 A project backed by Alphabet (Google's parent company) through its health-tech initiative is supporting a mosquito-control program designed to fight dangerous diseases. The mission? 🎯 ✅ Reduce dengue fever cases ✅ Help combat Zika virus outbreaks ✅ Lower West Nile virus transmission ✅ Reduce dependence on chemical pesticides Here's where things get interesting... 👀 ❌ These mosquitoes are NOT released to bite people. ❌ They're NOT part of a "mosquito invasion." ❌ The released mosquitoes are MALES. And male mosquitoes don't bite humans. 🦟🚫 Instead, they carry a naturally occurring bacterium called Wolbachia. When they mate with wild female mosquitoes: 📉 Eggs fail to hatch 📉 Mosquito populations gradually decline 📉 Disease-carrying mosquito numbers can be reduced over time 💡 Why are scientists exploring this? Because some mosquito species are becoming increasingly resistant to traditional pesticides. Rather than spraying more chemicals, researchers are testing biological solutions that may have a smaller environmental footprint. 🌎 🤔 The bigger question: If biotechnology could significantly reduce the spread of deadly mosquito-borne diseases... Would YOU support releasing millions of non-biting mosquitoes? 👇 🔥 YES — if it saves lives 😬 NO — too many unknown risks Drop your answer below and let's discuss! 💬 $STRAX {spot}(STRAXUSDT) #Technology | #Biotech | #NomuraOCCTrustBankApproval | #STRAX | #SoulThunder 📚 Sources: (US EPA Experimental Use Permit Notice, CDC Wolbachia Program, World Mosquito Program, USA Today Network Reporting)
🚨🦟 $GOOGL -BACKED MOSQUITO RELEASE? THE INTERNET IS PANICKING... BUT HERE'S WHAT THEY'RE NOT TELLING YOU 👀👇

32 MILLION mosquitoes could be released in parts of the U.S. 🇺🇸

Sounds terrifying, right? 😳


But before you imagine swarms of mutant insects taking over cities... there's a twist. 🧵👇

🔬 A project backed by Alphabet (Google's parent company) through its health-tech initiative is supporting a mosquito-control program designed to fight dangerous diseases.

The mission? 🎯

✅ Reduce dengue fever cases ✅ Help combat Zika virus outbreaks ✅ Lower West Nile virus transmission ✅ Reduce dependence on chemical pesticides

Here's where things get interesting... 👀

❌ These mosquitoes are NOT released to bite people. ❌ They're NOT part of a "mosquito invasion." ❌ The released mosquitoes are MALES.

And male mosquitoes don't bite humans. 🦟🚫

Instead, they carry a naturally occurring bacterium called Wolbachia.

When they mate with wild female mosquitoes:

📉 Eggs fail to hatch 📉 Mosquito populations gradually decline 📉 Disease-carrying mosquito numbers can be reduced over time

💡 Why are scientists exploring this?

Because some mosquito species are becoming increasingly resistant to traditional pesticides.

Rather than spraying more chemicals, researchers are testing biological solutions that may have a smaller environmental footprint. 🌎

🤔 The bigger question:

If biotechnology could significantly reduce the spread of deadly mosquito-borne diseases...

Would YOU support releasing millions of non-biting mosquitoes? 👇

🔥 YES — if it saves lives 😬 NO — too many unknown risks

Drop your answer below and let's discuss! 💬
$STRAX

#Technology | #Biotech | #NomuraOCCTrustBankApproval | #STRAX | #SoulThunder

📚 Sources: (US EPA Experimental Use Permit Notice, CDC Wolbachia Program, World Mosquito Program, USA Today Network Reporting)
$BIO {future}(BIOUSDT) The price is trading around 0.0326 USDT, continuing the decline after a strong momentum in mid-April. The short MA is below the long one - the structure remains bearish. The MACD shows negative momentum, the histogram is red, confirming the weakness of buyers. #BİO #Biotech #TradingTales
$BIO

The price is trading around 0.0326 USDT, continuing the decline after a strong momentum in mid-April. The short MA is below the long one - the structure remains bearish. The MACD shows negative momentum, the histogram is red, confirming the weakness of buyers.

#BİO #Biotech #TradingTales
$BIO {future}(BIOUSDT) BIO is doing exactly what a healthy trend does – keeping buying activity right near the support level. Each dip is defended faster than the previous one, and the structure has never been broken. Volume is increasing imperceptibly.   A break could open the way for an upside move, and the risk-reward ratio is clean from here. Do you support the bid or wait for a breakout?   #BIO #BİO #Biotech
$BIO

BIO is doing exactly what a healthy trend does – keeping buying activity right near the support level. Each dip is defended faster than the previous one, and the structure has never been broken. Volume is increasing imperceptibly.

A break could open the way for an upside move, and the risk-reward ratio is clean from here.

Do you support the bid or wait for a breakout?

#BIO #BİO #Biotech
·
--
Bullish
🚨 $MRNA {future}(MRNAUSDT) — CANCER VACCINE MILESTONE $MRNA has more than doubled since mid-August, fueled by the Moderna–Merck cancer vaccine Phase 3 success. 🔥 This marks a major milestone: the first Phase 3 efficacy readout for a therapeutic cancer vaccine. 📈 The move highlights how powerful clinical breakthroughs can be for biotech valuations. 👀 $MRNA remains one to watch as the market continues to price in the potential impact of this breakthrough. #MRNA #Biotech #CancerVaccine #StocksToBinance
🚨 $MRNA
— CANCER VACCINE MILESTONE

$MRNA has more than doubled since mid-August, fueled by the Moderna–Merck cancer vaccine Phase 3 success.

🔥 This marks a major milestone: the first Phase 3 efficacy readout for a therapeutic cancer vaccine.

📈 The move highlights how powerful clinical breakthroughs can be for biotech valuations.

👀 $MRNA remains one to watch as the market continues to price in the potential impact of this breakthrough.

#MRNA #Biotech #CancerVaccine #StocksToBinance
·
--
Bullish
Moderna and Merck’s mRNA cancer vaccine meets Phase 3 endpoints, sending Moderna shares sharply higher 🧬 Moderna and Merck said their personalized mRNA vaccine, intismeran autogene, combined with Keytruda met both the primary recurrence-free survival endpoint and the key secondary distant metastasis-free survival endpoint in the Phase 3 INTerpath-001 trial involving 1,137 patients with surgically resected melanoma. 📈 The result marks the first Phase 3 success for an mRNA-based cancer therapy and an individualized neoantigen vaccine, reinforcing the positive signal previously seen in the Phase 2b study. 💹 Market reaction was strong, with Moderna shares rising around 90–100%+ in premarket trading, while Merck gained roughly 6–9%. ⚠️ However, detailed data such as the hazard ratio and absolute benefit have not yet been released, while overall survival remains under follow-up. The longer-term impact will depend on the full dataset and regulatory progress. #Biotech $MRNAon $MRK.US $BNB
Moderna and Merck’s mRNA cancer vaccine meets Phase 3 endpoints, sending Moderna shares sharply higher

🧬 Moderna and Merck said their personalized mRNA vaccine, intismeran autogene, combined with Keytruda met both the primary recurrence-free survival endpoint and the key secondary distant metastasis-free survival endpoint in the Phase 3 INTerpath-001 trial involving 1,137 patients with surgically resected melanoma.

📈 The result marks the first Phase 3 success for an mRNA-based cancer therapy and an individualized neoantigen vaccine, reinforcing the positive signal previously seen in the Phase 2b study.

💹 Market reaction was strong, with Moderna shares rising around 90–100%+ in premarket trading, while Merck gained roughly 6–9%.

⚠️ However, detailed data such as the hazard ratio and absolute benefit have not yet been released, while overall survival remains under follow-up. The longer-term impact will depend on the full dataset and regulatory progress.

#Biotech $MRNAon $MRK.US $BNB
MRNAonAlpha
MRKUS-2.61%
Article
STOCKS | iShares Biotechnology ETF Rises 3.2%, State Street SPDR S&P Biotechnology ETF Gains 2.9%The iShares Biotechnology ETF experienced a notable rise of 3.2% in the market, according to Jin10, reflecting renewed investor interest in the biotech sector. On the same day, the State Street SPDR S&P Biotechnology ETF also gained 2.9%, indicating broad-based positive sentiment among biotech-focused funds. This rally suggests that investors are increasingly optimistic about the prospects of biotech companies, possibly driven by recent advancements, regulatory developments, or favorable earnings reports within the industry. The gains across these ETFs highlight a shift in market sentiment towards risk-on behavior in the healthcare and biotech sectors. The biotech ETFs' positive movement also underscores ongoing interest from institutional investors in healthcare innovation and emerging biotech firms. These funds often serve as barometers for broader industry confidence, and their gains may signal an upcoming period of increased activity and investment in biotech equities. Overall, the rise in both ETFs points to a potential rebound or sustained optimism in the biotech sector, which has faced volatility in recent months. Market participants will likely continue to monitor developments in biotechnology for clues on future investment trends. #Biotech #ETFs #MarketUpdate

STOCKS | iShares Biotechnology ETF Rises 3.2%, State Street SPDR S&P Biotechnology ETF Gains 2.9%

The iShares Biotechnology ETF experienced a notable rise of 3.2% in the market, according to Jin10, reflecting renewed investor interest in the biotech sector. On the same day, the State Street SPDR S&P Biotechnology ETF also gained 2.9%, indicating broad-based positive sentiment among biotech-focused funds.
This rally suggests that investors are increasingly optimistic about the prospects of biotech companies, possibly driven by recent advancements, regulatory developments, or favorable earnings reports within the industry. The gains across these ETFs highlight a shift in market sentiment towards risk-on behavior in the healthcare and biotech sectors.
The biotech ETFs' positive movement also underscores ongoing interest from institutional investors in healthcare innovation and emerging biotech firms. These funds often serve as barometers for broader industry confidence, and their gains may signal an upcoming period of increased activity and investment in biotech equities.
Overall, the rise in both ETFs points to a potential rebound or sustained optimism in the biotech sector, which has faced volatility in recent months. Market participants will likely continue to monitor developments in biotechnology for clues on future investment trends. #Biotech #ETFs #MarketUpdate
The biggest wealth transfer in crypto won't come from finance. It will come from biology. Everyone is fighting over decentralized exchanges and yield farming, while a massive capital rotation is quietly happening in Decentralized Science. The DeSci super-cycle is officially here. The traditional scientific funding model is a slow, bureaucratic nightmare. Brilliant researchers spend years begging centralized institutions for grants, while massive pharmaceutical monopolies lock life-saving patents behind closed doors. Blockchain infrastructure is completely restructuring this system. Through IP-NFTs, scientific research and medical patents are being tokenized on-chain. This means retail investors can directly fund early-stage biotech, longevity research, and rare disease treatments. If a decentralized research collective discovers a new chemical compound and licenses the intellectual property to a major pharma company, the token holders who funded the research capture the actual financial upside. You are no longer just betting on a software application; you are investing in the legal rights to medical progress. The transition from DeFi to DeSci is opening up venture-capital-level biotech opportunities to anyone with a crypto wallet. $NMR $RIF $BIO #Write2Earn #DeSci #Biotech #CryptoTrends
The biggest wealth transfer in crypto won't come from finance. It will come from biology.

Everyone is fighting over decentralized exchanges and yield farming, while a massive capital rotation is quietly happening in Decentralized Science. The DeSci super-cycle is officially here.

The traditional scientific funding model is a slow, bureaucratic nightmare. Brilliant researchers spend years begging centralized institutions for grants, while massive pharmaceutical monopolies lock life-saving patents behind closed doors.

Blockchain infrastructure is completely restructuring this system.

Through IP-NFTs, scientific research and medical patents are being tokenized on-chain. This means retail investors can directly fund early-stage biotech, longevity research, and rare disease treatments.

If a decentralized research collective discovers a new chemical compound and licenses the intellectual property to a major pharma company, the token holders who funded the research capture the actual financial upside. You are no longer just betting on a software application; you are investing in the legal rights to medical progress.

The transition from DeFi to DeSci is opening up venture-capital-level biotech opportunities to anyone with a crypto wallet.

$NMR $RIF $BIO
#Write2Earn #DeSci #Biotech #CryptoTrends
脑胶质瘤有救了!海思科创新药获突破性治疗认定,加速上市!🚀🧠 医药创新+区块链结合才是王道,$MED这类医疗代币值得关注!#生物科技 #DeFi Brain tumor treatment breakthrough! Haisco's drug gets fast-track approval. 🚀🧠 Pharma innovation + blockchain = future goldmine. Keep an eye on $MED! #Biotech #DeFi
脑胶质瘤有救了!海思科创新药获突破性治疗认定,加速上市!🚀🧠 医药创新+区块链结合才是王道,$MED这类医疗代币值得关注!#生物科技 #DeFi

Brain tumor treatment breakthrough! Haisco's drug gets fast-track approval. 🚀🧠 Pharma innovation + blockchain = future goldmine. Keep an eye on $MED! #Biotech #DeFi
逢时科技启动上市辅导啦!这家做南极磷虾生物制品的创新企业要登陆资本市场了,海洋科技领域又添新力量!#生物科技 #海洋科技 $OCEAN Fengshi Tech just kicked off IPO prep! This innovative company focusing on Antarctic krill biotech products is heading to the capital markets. Ocean tech sector just got stronger! #Biotech #MarineTech $OCEAN
逢时科技启动上市辅导啦!这家做南极磷虾生物制品的创新企业要登陆资本市场了,海洋科技领域又添新力量!#生物科技 #海洋科技 $OCEAN

Fengshi Tech just kicked off IPO prep! This innovative company focusing on Antarctic krill biotech products is heading to the capital markets. Ocean tech sector just got stronger! #Biotech #MarineTech $OCEAN
📈 #ModernaRisesOver12% — Biotech Giant Surges on New Pipeline Data Moderna shares jumping over 12% after positive clinical trial data for its next-generation mRNA vaccine pipeline. Investors piling back into biotech as Moderna demonstrates progress beyond COVID-19 vaccines. #ModernaRisesOver12% #Biotech #MRNA
📈 #ModernaRisesOver12% — Biotech Giant Surges on New Pipeline Data

Moderna shares jumping over 12% after positive clinical trial data for its next-generation mRNA vaccine pipeline. Investors piling back into biotech as Moderna demonstrates progress beyond COVID-19 vaccines.

#ModernaRisesOver12% #Biotech #MRNA
MRNAonAlpha
MRNAUS-4.09%
🍄 Пітер Брандт говорить про «магічні гриби». А що, якщо справжні гриби вже стають технологією? У крипті 🍄 — це метафора самообману: коли інвестор бачить лише $1 млн за BTC і перестає помічати ризики. Але в реальному світі гриби — це вже біотехнології, нові матеріали та AI. Mushrooms Inc. (OTC: MSRM) повідомила про Proof of Concept MycoLabX: міцеліальні плівки продемонстрували зміну кольору при взаємодії з бактеріями. Потенційне застосування — технології для раннього виявлення інфекцій, зокрема у догляді за ранами. Паралельно компанія розвиває MycoLab.ai — AI-платформу для роботи з науковими даними про мікологію. Але DVA нагадує: Proof of Concept ≠ готовий продукт. Технологія ≠ комерційний успіх. OTC-акція ≠ гарантований прибуток. MSRM — дуже мала й високоризикова компанія. Тому стежимо не за красивою історією, а за фактами: незалежною валідацією, партнерами, фінансуванням і реальною комерціалізацією. 🍄 Гриби можуть бути технологією. Але інвестор не повинен сам ставати грибом. DVA — факти без хайпу. Не фінансова порада. Збереження цінностей та часу. #DVA #Biotech #AI #Mycelium #MSRM
🍄 Пітер Брандт говорить про «магічні гриби». А що, якщо справжні гриби вже стають технологією?

У крипті 🍄 — це метафора самообману: коли інвестор бачить лише $1 млн за BTC і перестає помічати ризики.

Але в реальному світі гриби — це вже біотехнології, нові матеріали та AI.

Mushrooms Inc. (OTC: MSRM) повідомила про Proof of Concept MycoLabX: міцеліальні плівки продемонстрували зміну кольору при взаємодії з бактеріями. Потенційне застосування — технології для раннього виявлення інфекцій, зокрема у догляді за ранами.

Паралельно компанія розвиває MycoLab.ai — AI-платформу для роботи з науковими даними про мікологію.

Але DVA нагадує:

Proof of Concept ≠ готовий продукт.
Технологія ≠ комерційний успіх.
OTC-акція ≠ гарантований прибуток.

MSRM — дуже мала й високоризикова компанія. Тому стежимо не за красивою історією, а за фактами: незалежною валідацією, партнерами, фінансуванням і реальною комерціалізацією.

🍄 Гриби можуть бути технологією.
Але інвестор не повинен сам ставати грибом.

DVA — факти без хайпу.

Не фінансова порада.
Збереження цінностей та часу.

#DVA #Biotech #AI #Mycelium #MSRM
$BIO {future}(BIOUSDT) Trading volumes remain stable, without sharp sales spikes. The structure indicates the formation of higher lows and higher highs. Buyers are actively defending the entry zones, not allowing prices to fall. In the event of a resistance breakdown, the momentum can accelerate significantly. #BIO #BİO #Biotech
$BIO

Trading volumes remain stable, without sharp sales spikes. The structure indicates the formation of higher lows and higher highs. Buyers are actively defending the entry zones, not allowing prices to fall. In the event of a resistance breakdown, the momentum can accelerate significantly.

#BIO #BİO #Biotech
🚨 $XBI {future}(XBIUSDT) USDT Perp is almost live on Binance Futures 🚨 Another fresh listing is about to hit the board — XBIUSDT Perpetual is counting down and the market is getting ready. 👀🔥 Pair: XBIUSDT Perp Underlying asset: SPDR S&P Biotech ETF (XBI) Platform: Binance Futures Status: Pre-launch / trading not open yet Countdown shown: 01 Hour 25 Min 44 Sec remaining at the time of screenshot Right now, price and market stats are still inactive: Last Price: 0.00 Mark Price: 0.00 24h High / Low: 0.00 / 0.00 24h Volume: 0.00 That usually means the contract page is live before actual trading starts, giving traders time to prepare for the opening volatility. Since XBI tracks the biotech sector, this launch is interesting because it brings a traditional biotech ETF exposure into perpetual futures trading format. What to watch at open: First few candles for volatility spike Funding and liquidity behavior Early long/short battle after listing goes live Binance is opening the door for biotech-linked perp action — XBIUSDT could get very wild right after launch. 📈⚡ #Binance #Futures #XBIUSDT #Perpetual #CryptoTrading #Biotech ParadigmRaises$1.2BThirdFundForAIAndRobotics #FedMinutesShowSplitOnRateHikes #SonyGetsOCCApprovalForStablecoinTrust #KOSPIJumpsNearly4%To7539 #SKHynixUSListingOversubscribed7x
🚨 $XBI
USDT Perp is almost live on Binance Futures 🚨

Another fresh listing is about to hit the board — XBIUSDT Perpetual is counting down and the market is getting ready. 👀🔥

Pair: XBIUSDT Perp
Underlying asset: SPDR S&P Biotech ETF (XBI)
Platform: Binance Futures
Status: Pre-launch / trading not open yet
Countdown shown: 01 Hour 25 Min 44 Sec remaining at the time of screenshot

Right now, price and market stats are still inactive:

Last Price: 0.00

Mark Price: 0.00

24h High / Low: 0.00 / 0.00

24h Volume: 0.00

That usually means the contract page is live before actual trading starts, giving traders time to prepare for the opening volatility. Since XBI tracks the biotech sector, this launch is interesting because it brings a traditional biotech ETF exposure into perpetual futures trading format.

What to watch at open:

First few candles for volatility spike

Funding and liquidity behavior

Early long/short battle after listing goes live

Binance is opening the door for biotech-linked perp action — XBIUSDT could get very wild right after launch. 📈⚡
#Binance #Futures #XBIUSDT #Perpetual #CryptoTrading #Biotech
ParadigmRaises$1.2BThirdFundForAIAndRobotics

#FedMinutesShowSplitOnRateHikes
#SonyGetsOCCApprovalForStablecoinTrust
#KOSPIJumpsNearly4%To7539
#SKHynixUSListingOversubscribed7x
Log in to explore more content
Join global crypto users on Binance Square
⚡️ Get latest and useful information about crypto.
💬 Trusted by the world’s largest crypto exchange.
👍 Discover real insights from verified creators.
Email / Phone number